. Author manuscript; available in PMC: 2016 Nov 1.

Published in final edited form as: J Clin Pharmacol. 2015 Jun 26;55(11):1303–1312. doi: 10.1002/jcph.543

Table 3.

Parameter estimates, bootstrap results and p-values for covariates included in the final model

Parameter	θ estimate^a	Bootstrap Mean (95% CI)	p-value^b
EIAED (+) status
CL_irinotecan	0.194	0.193 (0.088, 0.293)	< 0.0001
CL_SN-38 / F_SN-38	1.03	1.06 (0.678, 1.51)	< 0.0001
CL_SN-38G / F_SN-38G	0.248	0.270 (−0.027, 0.641)	0.001
Steroid (+) status
CL_APC / F_APC	0.262	0.267 (0.051, 0.504)	0.006
Female sex
CL_SN-38 / F_SN-38	−0.247	−0.243 (−0.394, −0.092)	0.001
CL_SN-38G / F_SN-38G	−0.381	−0.377 (−0.493, −0.242)	< 0.0001
Grade 2 disease (at initial diagnosis)
CL_irinotecan	0.169	0.171 (0.072, 0.273)	0.001

θ indicates fractional change compared to male, EIAED(-), steroid(-), non-grade 2 patients

p-value calculated from stepwise deletion phase using the likelihood ratio test